Roche Diagnostics has a proud tradition of innovation in healthcare around the globe. We are committed to making a real difference in people’s lives by providing products and services for the diagnosis of diseases. One of our objectives is to develop new diagnostic tools to support healthcare professionals and patients, in their efforts to manage diseases and healthcare costs.
Our leadership in innovation is evident in our Early Infant Diagnosis of HIV program built on our globally renowned Polymerase Chain Reaction (PCR) technology. The introduction of a Dried Blood Spot (DBS) sampling option for this program has had a direct benefit for all stakeholders in the healthcare industry namely, patients, clinicians, administrators and program funders.
Roche Diagnostics’ adoption of innovation within these programs is not limited to the development of in-vitrodiagnostic assays for high burden diseases such as HIV/AIDS and TB, but also encompasses other aspects of process workflow in an effort to create sustainable solutions for the challenges posed within resource-limited regions. This is achieved through the AmpliCare Initiative, which was our proactive response to the need to expand diagnostics to these settings.
We are committed to capacity building initiatives through ongoing certified training of laboratory scientists at the Roche PCR Academy in Johannesburg, to ensure highest results, quality and reliability. This training includes education of Health Care Professionals on molecular theory and techniques enabling them to deliver better patient management outcomes.
Through Roche’s research and development initiatives, we also apply our expertise to develop novel solutions, precise and robust diagnostic tests, automated systems and integrated solutions in the fields of Clinical Chemistry, Hematology, Coagulation and Immunodiagnostics.
We believe that through continued effort and investment in the latest innovations in diagnostics, Roche can make a positive, sustainable and cost-effective contribution to developing world healthcare.
Roche Diagnostics is the world leader in in vitro diagnostics. Roche Diagnostics offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories in the fields of diabetes care and anticoagulation therapy, molecular biology, clinical chemistry, immunology and applied science.
Contact Details
Roche Products (Pty) Ltd
9 Will Scarlet Road
P O Box 1927,Randburg
2125, South Africa
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
